FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37726862> ?p ?o ?g. }

• Q37726862 description "article científic" @default.
• Q37726862 description "article scientifique" @default.
• Q37726862 description "articolo scientifico" @default.
• Q37726862 description "artigo científico" @default.
• Q37726862 description "artículu científicu espublizáu en 2014" @default.
• Q37726862 description "bilimsel makale" @default.
• Q37726862 description "scientific article published on March 2014" @default.
• Q37726862 description "vedecký článok" @default.
• Q37726862 description "vetenskaplig artikel" @default.
• Q37726862 description "videnskabelig artikel" @default.
• Q37726862 description "vědecký článek" @default.
• Q37726862 description "wetenschappelijk artikel" @default.
• Q37726862 description "wissenschaftlicher Artikel" @default.
• Q37726862 description "наукова стаття, опублікована в березні 2014" @default.
• Q37726862 description "научни чланак" @default.
• Q37726862 description "مقالة علمية نشرت في مارس 2014" @default.
• Q37726862 name "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 name "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 name "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 type Item @default.
• Q37726862 label "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 label "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 label "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 prefLabel "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 prefLabel "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 prefLabel "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 P1433 Q37726862-FFC42163-6518-408B-A77F-A05AF1A824D0 @default.
• Q37726862 P1476 Q37726862-62E1F33F-2CEC-4C19-9786-E7B6CF42D44E @default.
• Q37726862 P2093 Q37726862-0AE41E8F-C503-404E-B6B5-BCFF9304D757 @default.
• Q37726862 P2093 Q37726862-328BBB16-E174-4078-A96A-F613E7EA49DE @default.
• Q37726862 P2093 Q37726862-77C952C6-D523-4757-8FEA-52E469649F59 @default.
• Q37726862 P2093 Q37726862-801D3F91-F897-475C-927A-B015596316A8 @default.
• Q37726862 P2093 Q37726862-A1CC9C65-967E-4AAC-B4E0-C0B23A4366DF @default.
• Q37726862 P2093 Q37726862-B76C3901-6EB0-4327-A4D5-7B1F46BD80E5 @default.
• Q37726862 P2093 Q37726862-CC6048DD-7976-42F7-AEC8-9D9D06F069CD @default.
• Q37726862 P2093 Q37726862-D2FD0DC5-57A3-4973-BEC9-FCF2B0B876B5 @default.
• Q37726862 P2860 Q37726862-006FDABF-FAC3-4353-8E7E-C9BC54D046BA @default.
• Q37726862 P2860 Q37726862-0D2F4CE8-EAB0-4679-9AAD-A2A07C51C16C @default.
• Q37726862 P2860 Q37726862-10B5F9B6-963D-4A35-BBB6-D9F4968B2BA3 @default.
• Q37726862 P2860 Q37726862-123A5E03-5C17-4483-A589-3EE8EEBCF5A2 @default.
• Q37726862 P2860 Q37726862-16CC106B-FCF4-414C-9123-8C59A644BCD5 @default.
• Q37726862 P2860 Q37726862-2459C3D5-BB79-4779-8B05-692B96A8B73D @default.
• Q37726862 P2860 Q37726862-283073C0-687D-44BF-8A79-1E5B7125BFC2 @default.
• Q37726862 P2860 Q37726862-2FC6BCFE-B950-4BED-95B9-70AD8FB077B2 @default.
• Q37726862 P2860 Q37726862-2FD6A2B3-3DBB-4000-9EA1-E0FC73BD1729 @default.
• Q37726862 P2860 Q37726862-54A548A9-830D-41D5-B4B5-FDBCB602410D @default.
• Q37726862 P2860 Q37726862-592671B3-4977-4DC9-9CE3-044EAC9279F7 @default.
• Q37726862 P2860 Q37726862-5FEBCEA2-DBE3-46D6-B2D9-46158172EEA9 @default.
• Q37726862 P2860 Q37726862-64B712B9-D3CC-4322-8235-4FF0F5ADB036 @default.
• Q37726862 P2860 Q37726862-67C917D1-C09D-4A4A-89BF-322AEFF79B0A @default.
• Q37726862 P2860 Q37726862-69CCBDD1-1CAE-4666-A102-1F4F3603F26F @default.
• Q37726862 P2860 Q37726862-763931CC-1107-4C4A-85C1-25F03AFD72AF @default.
• Q37726862 P2860 Q37726862-7FF40E63-52D0-40CD-9226-DF1576408B87 @default.
• Q37726862 P2860 Q37726862-92E3F531-6AE6-441C-8AF7-F1B79BDB6AF2 @default.
• Q37726862 P2860 Q37726862-A34AA2F8-8C36-42F7-B606-98A8032311C9 @default.
• Q37726862 P2860 Q37726862-AAE839E8-69E5-439F-8CC1-6480083EC97E @default.
• Q37726862 P2860 Q37726862-C3110FC7-3AC4-4DC0-A855-EF6B4BBA70FB @default.
• Q37726862 P2860 Q37726862-C3406CB0-B985-4402-A6A3-036E3C6E4006 @default.
• Q37726862 P2860 Q37726862-D7E5A59D-D04D-49AB-B689-DFDCDBA87F71 @default.
• Q37726862 P2860 Q37726862-E1CCF261-665F-47EF-88B1-FE19291AF174 @default.
• Q37726862 P2860 Q37726862-F1637542-ED69-469F-BCEF-8F68E50DB383 @default.
• Q37726862 P2860 Q37726862-FE1D9709-2049-433A-BFE4-3D20BE626C28 @default.
• Q37726862 P2860 Q37726862-FF6367E3-A366-4091-A030-CAC8081E4A5B @default.
• Q37726862 P304 Q37726862-F5BECD68-725E-4C0B-99CF-7704F48479E9 @default.
• Q37726862 P31 Q37726862-06AC91EF-3AB0-441B-A436-08C3E8B497BE @default.
• Q37726862 P356 Q37726862-87C8441B-17C4-4FD2-BB51-FDC98D8990F2 @default.
• Q37726862 P433 Q37726862-0F1A9FEC-ED6A-409F-959C-EB3914D6A690 @default.
• Q37726862 P478 Q37726862-29541AC2-16A6-4AFC-A350-4307ED009855 @default.
• Q37726862 P577 Q37726862-F3D2AF16-B531-4422-9E5A-03C8AE69DFB9 @default.
• Q37726862 P5875 Q37726862-61F6C0DE-8ADD-46F9-9A57-9E553638E6E6 @default.
• Q37726862 P698 Q37726862-1C1A6720-6849-4F01-96DE-20C41324C21A @default.
• Q37726862 P932 Q37726862-F600EBBC-325B-44B1-BBF3-58D57E3F7F49 @default.
• Q37726862 P356 CUAJ.1356 @default.
• Q37726862 P698 24839481 @default.
• Q37726862 P1433 Q26842808 @default.
• Q37726862 P1476 "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• Q37726862 P2093 "Annette Schröder" @default.
• Q37726862 P2093 "Eve Pellerin" @default.
• Q37726862 P2093 "Geneviève Nadeau" @default.
• Q37726862 P2093 "Katherine Moore" @default.
• Q37726862 P2093 "Lucie Genois" @default.
• Q37726862 P2093 "Micheline Hamel" @default.
• Q37726862 P2093 "Pascale Lamontagne" @default.
• Q37726862 P2093 "Stéphane Bolduc" @default.
• Q37726862 P2860 Q28277963 @default.
• Q37726862 P2860 Q31931319 @default.
• Q37726862 P2860 Q34282589 @default.
• Q37726862 P2860 Q34550245 @default.
• Q37726862 P2860 Q34568111 @default.
• Q37726862 P2860 Q35903871 @default.
• Q37726862 P2860 Q36528534 @default.
• Q37726862 P2860 Q36608356 @default.
• Q37726862 P2860 Q37535961 @default.
• Q37726862 P2860 Q37991417 @default.
• Q37726862 P2860 Q38047534 @default.
• Q37726862 P2860 Q38390033 @default.
• Q37726862 P2860 Q40714098 @default.
• Q37726862 P2860 Q42930615 @default.
• Q37726862 P2860 Q43288762 @default.
• Q37726862 P2860 Q44246206 @default.

• next